TY - JOUR
T1 - The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer
AU - Garg, Scot
AU - Wykrzykowska, Joanna
AU - Serruys, Patrick W.
AU - de Vries, Ton
AU - Buszman, Pawel
AU - Trznadel, Stanislaw
AU - Linke, Axel
AU - Lenk, Karsten
AU - Ischinger, Thomas
AU - Klauss, Volker
AU - Eberli, Franz
AU - Corti, Roberto
AU - Wijns, William
AU - Morice, Marie-Claude
AU - di Mario, Carlo
AU - Tyczynski, Pawel
AU - van Geuns, Robert Jan
AU - Eerdmans, Pedro
AU - van Es, Gerrit-Anne
AU - Meier, Bernhard
AU - Jüni, Peter
AU - Windecker, Stephan
PY - 2011/3
Y1 - 2011/3
N2 - Aims: This study investigated the differences in clinical outcomes between patients with bifurcation lesions (BL) treated with a biolimus-eluting stent (BES) with a biodegradable polymer, and a sirolimus-eluting stent (SES) with a durable polymer. Methods and results: The clinical outcomes were assessed in the 497 patients (BES 258, SES 239) enrolled in the multicentre, randomised LEADERS trial who underwent treatment of Y1 BL (total=534 BL). At 12-months follow-up there was no significant difference in the primary endpoint of MACE, a composite of cardiac death, myocardial infarction and clinically indicated target vessel revascularisation (BES 12.8% vs. SES 16.3%, p=0.31). Patients treated with BES had comparable rates of cardiac death (BES 2.7% vs. SES 2.9%, p=1.00), numerically higher rates of myocardial infarction (BES 8.9% vs. SES 5.4%, p=0.17), and significantly lower rates of clinically indicated target vessel revascularisation (4.3% vs. 11.3%, p=0.004) when compared to those treated with SES. The rate of stent thrombosis at 12-months was 4.3% and 3.8% for BES and SES, respectively (p=0.82). Conclusions: In the treatment of BL the use of BES lead to superior efficacy and comparable safety compared to SES. © Europa Edition 2011. All rights reserved.
AB - Aims: This study investigated the differences in clinical outcomes between patients with bifurcation lesions (BL) treated with a biolimus-eluting stent (BES) with a biodegradable polymer, and a sirolimus-eluting stent (SES) with a durable polymer. Methods and results: The clinical outcomes were assessed in the 497 patients (BES 258, SES 239) enrolled in the multicentre, randomised LEADERS trial who underwent treatment of Y1 BL (total=534 BL). At 12-months follow-up there was no significant difference in the primary endpoint of MACE, a composite of cardiac death, myocardial infarction and clinically indicated target vessel revascularisation (BES 12.8% vs. SES 16.3%, p=0.31). Patients treated with BES had comparable rates of cardiac death (BES 2.7% vs. SES 2.9%, p=1.00), numerically higher rates of myocardial infarction (BES 8.9% vs. SES 5.4%, p=0.17), and significantly lower rates of clinically indicated target vessel revascularisation (4.3% vs. 11.3%, p=0.004) when compared to those treated with SES. The rate of stent thrombosis at 12-months was 4.3% and 3.8% for BES and SES, respectively (p=0.82). Conclusions: In the treatment of BL the use of BES lead to superior efficacy and comparable safety compared to SES. © Europa Edition 2011. All rights reserved.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79954514802&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/21330239
U2 - https://doi.org/10.4244/EIJV6I8A162
DO - https://doi.org/10.4244/EIJV6I8A162
M3 - Article
C2 - 21330239
SN - 1774-024X
VL - 6
SP - 928
EP - 935
JO - Eurointervention
JF - Eurointervention
IS - 8
ER -